Fig. 1

Before-and-after plots of Ig serum concentrations in sCAP patients treated with placebo or trimodulin. The kinetics of immunoglobulins during infection was investigated in serum of patients with sCAP in the PK subset (n = 21). On day 5, in sCAP patients treated with trimodulin, A median levels of IgM increased from 0.5 to 1.9 g/L, B median levels of IgG increased from 8.0 to 11.7 g/L, and C median levels of IgA increased from 2.5 to 3.8 g/L. Baseline is the pre-dose level measured before start of infusion on Day 1 (trimodulin n = 9, placebo n = 10) while Day 5 is the post-dose level taken after the infusion ended (trimodulin n = 10, placebo n = 9). On Day 7 data were available for trimodulin n = 10, placebo n = 7, and on Day 21 for trimodulin n = 6, placebo n = 5 patients. Complete before-and-after-plots were possible for five trimodulin- and four placebo-treated patients (indicated by linked Day 1, 5, 7 and Day 21 data points). Dotted lines indicate normal reference ranges (Table 2, [41]). Ig immunoglobulin, PK pharmacokinetics, sCAP severe community-acquired pneumonia